Reverse Engineering Return On Equity Financial ratios

New Post Public Reply Private Reply Replies (0) Message Board
NITE

Reverse Engineering Return On Equity
Financial ratios are used both internally by chief executive officers (CEOs), chief financial officers (CFOs), accountants and financial managers , as well as externally by accountants and security analysts. They can be used to gauge the effectiveness of a management team, or to evaluate the value of the company's stock for purchase or sale. Ratios are generally accepted across many disciplines and provide an efficient way to organize large amounts of information into readable and analyzable output. While return on equity (ROE) has outstanding evaluation and predictive qualities, return on net operating assets (RNOA) complements ROE, filling in the gaps and assisting in the analysis of management's ability to run a company. In this article we'll explain how interpreting the numbers provides an in-depth evaluation of management's success in creating profitability and provides insight into long-term future growth rates. (To learn more, read Keep Your Eyes on The ROE.)


Return on Equity (ROE)
ROE is one of the most commonly used and recognized ratios to analyze the profitability of a business. To the common stockholder , it is an indication of how effective management has been with shareholders' capital after excluding payments to all other net capital contributors.

To derive and differentiate ROE from return on total equity:


Then to make an accurate measure of the common shareholders measure:


Since ROE is an important indicator of performance, it is necessary to break the ratio into several components to provide an explanation of a firm's ROE. The DuPont model, created in 1919 by an executive at E.I. du Pont de Nemours & Co., breaks ROE into two ratios:


This reveals that ROE equals net profit margin times the equity turnover. The basic premise of the model implies that management has two options to increase its ROE and thus increase value to its shareholders:
• Increase the company's equity turnover and use equity more efficiently
• Become more profitable and subsequently increase the company's net profit margin (For further reading, see The Bottom Line on Margins.)
One of the most common ways to increase the efficiency of assets is to leverage them. Breaking down ROE even more reveals:


Flaws in ROE
While the DuPont formula has proved useful for many years, it is flawed in its inability to separate the decisions regarding both operating and financing changes. For example, an analyst noting a decline in return on assets (ROA) might conclude that the company is experiencing lower operating performance when ROE increased through the use of leverage.

Return on Net Operating Assets (RNOA)
RNOA, on the other hand, successfully separates financing and operating decisions and measures their effectiveness.

RNOA = Operating Income (After Tax) / Net Operating Assets (NOA)

By isolating the NOA, no incorrect conclusions can be drawn from the ratio analysis, thus repairing the missing link form the original DuPont model. Isolating the components also means that changing debt levels do not change operating assets (OA), the profit before interest expense, and the RNOA.
ROE = RNOA + (FLEV X Spread)

OR

= Return From Operating Activities + Return From Non-Operating Activities (Financing)

Comparing Companies
The best way to understand RNOA and ROE is to compare historical periods across many companies: For a 34-year period counting back from 2008, the median ROE achieved by all publicly traded U.S. companies was 12.2%. This ROE is driven by RNOA as illustrated in the following median values:
ROE Disaggregation* ROE = RNOA + (FLEV x Spread)
First Quartile (25th percentile) 6.3% 6.0% 0.05 x 0.5%
Median (50th percentile) 12.2% 10.3% 0.40 x 3.3%
Third Quartile (75th percentile 17.6% 15.6% 0.93 x 10.3%
*Numbers in the table are medians (50th percentile) and quartiles (25th or 75th percentile); thus, the equation does not exactly equal ROE.

The data shows that companies in general are financed rather conservatively as expressed with FLEV< 1.0 and have greater portions of equity in their capital structures. On average, companies are rewarded with a positive spread on money borrowed at 3.3% - but this is not always the case, as seen in the lowest 25% of companies. The most important conclusion from the output is that RNOA averages approximately 84% of ROE (10.3% / 12.2%). (To learn more, read Analyze Investments Quickly With Ratios.)

Bottom Line
ROE is a widely used financial ratio used to evaluate management's ability to run a company. Unfortunately, comparing the ratios between two companies or year over year might lead to the wrong conclusion based solely on those results. The DuPont formula does not separate the operating and non-operating performance and it allows the use of leverage to misrepresent the results. (To learn more, see Spot Quality With ROIC.)

Taking the model one step farther by analyzing RNOA provides a much clearer picture of performance by focusing on operational functions. Once ROE is broken down into RNOA, FLEV and Spread, one can make more accurate predictions of long-term future growth rates using the formula's output.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading